The National Cancer Institute in Misrata has raised alarms over the importation of suspicious and unverified cancer treatments, halting their distribution due to safety concerns.
A report from the institute revealed that the drugs, sourced from companies in India, Cyprus, Turkey, and Malta, were of questionable quality and unknown origins.
According to the institute’s scientific committee, these medications triggered adverse reactions, including allergic responses and worsening symptoms, among cancer patients.
The committee has strongly recommended that Libya source cancer treatments from globally recognized pharmaceutical companies to ensure the safety and effectiveness of patient care.
Health
